A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Basit Öğe Kaydı
dc.authorid0000-0003-2538-8569
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorÖztürk, Akın
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorPaydaş, Semra
dc.contributor.authorÇılbır, Ebru
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorUysal, Mükremin
dc.contributor.authorYeşil Çınkır, Havva
dc.contributor.authorÜskent, Necdet
dc.contributor.authorDemir, Necla
dc.contributor.authorSakin, Abdullah
dc.contributor.authorDursun, Oldaç Uras
dc.contributor.authorAver, Birkan
dc.contributor.authorTurhal, Nazım Serdar
dc.contributor.authorKeskin, Serkan
dc.contributor.authorTural, Deniz
dc.contributor.authorEralp, Yeşim
dc.contributor.authorBuğdaycı Başal, Fatma
dc.contributor.authorYaşar, Hatime Arzu
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorDemirci, Umut
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorÇakar, Burcu
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorYetişyiğit, Tarkan
dc.contributor.authorUrvay, Semiha
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorOyan, Başak
dc.contributor.authorTurna, Zeynep Hande
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorŞeker, Mehmet Metin
dc.contributor.authorÜnal, Olçun Ümit
dc.contributor.authorMeydan, Nezih
dc.contributor.authorOkutur, Sadi Kerem
dc.contributor.authorTunalı, Didem
dc.contributor.authorErman, Mustafa
dc.date.accessioned2024-06-11T07:55:45Z
dc.date.available2024-06-11T07:55:45Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractTo evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers - a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.
dc.identifier.citationKılıçkap, S., Öztürk, A., Karadurmuş, N., Korkmaz, T., Yumuk, P. F., Çiçin, İ. ... Erman, M. (2024). A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy. Medicine (United States), 103(21), E37972. http://dx.doi.org/10.1097/MD.0000000000037972
dc.identifier.doi10.1097/MD.0000000000037972
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue21
dc.identifier.pmid38787994
dc.identifier.scopus2-s2.0-85194219961
dc.identifier.scopusqualityQ3
dc.identifier.startpageE37972
dc.identifier.urihttp://dx.doi.org/10.1097/MD.0000000000037972
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12613
dc.identifier.volume103
dc.identifier.wos001230616700060en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSakin, Abdullah
dc.institutionauthorÖlmez, Ömer Fatih
dc.language.isoen
dc.relation.ispartofMedicine (United States)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectLung Cancer Patients
dc.subjectALK
dc.titleA multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sakin-Abdullah-2024.pdf
Boyut:
695.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu